The proliferation of TF-1 cells treated with increasing concentrations of hIL-3 was assessed. After 48 hour treatment with hIL-3, cells were incubated with a tetrazolium salt and the OD450 - OD650 was determined.
The purity of recombinant hIL-3 was determined by SDS-PAGE of 6 µg reduced (+) and non-reduced (-) recombinant hIL-3 and staining overnight with Coomassie Blue.
Western blot analysis of extracts from TF-1 cells untreated or treated with hIL-3 for 15 minutes, using Phospho-Stat5 (Tyr694) (C11C5) Rabbit mAb #9359 (upper) and Stat5 (3H7) Rabbit mAb #9358 (lower).
With carrier: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2 containing 20 μg BSA per 1 μg hIL-3. Carrier free: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2.
Stable in lyophilized state at -20°C for 1 year after receipt. Sterile stock solutions reconstituted with carrier protein are stable at 4°C for 2 months and at -20°C for 6 months. Avoid repeated freeze-thaw cycles. Maintain sterility. Storage at -20°C should be in a manual defrost freezer.
>98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant hIL-3. All lots are greater than 98% pure.
Less than 0.01 ng endotoxin/1 μg hIL-3.
The bioactivity of recombinant hIL-3 was determined in a TF-1 cell proliferation assay. The ED50 of each lot is between 50 -400 pg/ml.
Recombinant hIL-3 contains no "tags" and the nonglycosylated protein has a calculated MW of 15,091. DTT-reduced and non-reduced protein migrate as 26 kDa polypeptides. Lower mobility and heterogeneity in SDS PAGE are due to glycosylation. The expected amino-terminal APMTQ of recombinant hIL-3 was verified by amino acid sequencing.
Recombinant human interleukin-3 (hIL-3) Ala20-Phe152 (Accession # NP_000579) was expressed in human 293 cells at Cell Signaling Technology.
IL-3 is produced by T cells, mast cells and eosinophils (1). Target cells include hematopoietic progenitors, neutrophils, macrophages, mast cells, eosinophils, lymphoid and erythroid cells (1). The IL-3 receptor is a heterodimer of the IL-3 specific α-chain and the common β-chain, βc, which is also used by GM-CSF and IL-5. (1). Binding of IL-3 can also involve substitution of the βc by a βIL-3-chain that appears to be specific for IL-3 (1,2). Binding of IL-3 to its cognate receptor(s) induces activation of Jak2, phosphorylation of multiple Stats (1,3,5,6), and the PI3K/Akt pathway (1). IL-3 may play an important role in the development of airway inflammation associated with asthma (3,4,5).
Explore pathways + proteins related to this product.
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST's products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST's Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.